Plasma high density lipoprotein cholesterol in streptozotocin diabetic and non-diabetic mice after prolonged administration of glibenclamide, chlorpropamide and metformin.
A possible influence of oral hypoglycaemic drugs on plasma high density lipoprotein cholesterol (HDL-C) concentrations was examined in streptozotocin diabetic and non-diabetic mice. Treatment of streptozotocin diabetic mice with glibenclamide (0.4 mg/kg/day), chlorpropamide (10 mg/kg/day) or metformin (60 mg/kg/day) for 28 weeks did not significantly alter plasma total cholesterol (TC) or HDL-C in streptozotocin diabetic mice. Plasma TC and HDL-C were not related to the prevailing plasma glucose concentration. Non-diabetic mice treated with glibenclamide or metformin for 46 weeks showed no changes in TC or HDL-C. However, chlorpropamide increased TC and HDL-C, and lowered the TC : HDL-C molar ration after 46 weeks in non-diabetic mice. The effect of chlorpropamide was associated with an excessive gain in weight.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002747:Chlorpropamide / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D005905:Glyburide / Q000494:pharmacology*; D007700:Kinetics; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008687:Metformin / Q000494:pharmacology*; D051379:Mice
D001786:Blood Glucose; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D008687:Metformin; D002784:Cholesterol; D005905:Glyburide; D002747:Chlorpropamide